These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24884504)

  • 1. TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.
    Jørgensen CL; Bjerre C; Ejlertsen B; Bjerre KD; Balslev E; Bartels A; Brünner N; Nielsen DL
    BMC Cancer; 2014 May; 14():360. PubMed ID: 24884504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.
    Nielsen DL; Bjerre KD; Jakobsen EH; Cold S; Stenbygaard L; Sørensen PG; Kamby C; Møller S; Jørgensen CL; Andersson M
    J Clin Oncol; 2011 Dec; 29(36):4748-54. PubMed ID: 22084374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients.
    Jørgensen CL; Nielsen TO; Bjerre KD; Liu S; Wallden B; Balslev E; Nielsen DL; Ejlertsen B
    Acta Oncol; 2014 Jun; 53(6):776-87. PubMed ID: 24359601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.
    Seidman AD; Chan S; Wang J; Zhu C; Xu C; Xu B
    Oncologist; 2014 May; 19(5):443-52. PubMed ID: 24705980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.
    Jørgensen CL; Ejlertsen B; Bjerre KD; Balslev E; Nielsen DL; Nielsen KV
    BMC Cancer; 2013 Nov; 13():541. PubMed ID: 24215511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.
    Seidman AD; Brufsky A; Ansari RH; Hart LL; Stein RS; Schwartzberg LS; Stewart JF; Russell CA; Chen SC; Fein LE; De La Cruz Vargas JA; Kim SB; Cavalheiro J; Zhao L; Gill JF; Obasaju CK; Orlando M; Tai DF
    Ann Oncol; 2011 May; 22(5):1094-1101. PubMed ID: 21084429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients.
    Tanaka K; Joyama S; Chuman H; Hiraga H; Morioka H; Yoshikawa H; Hosaka M; Takahashi M; Kubo T; Hatano H; Kaya M; Toguchida J; Nishida Y; Nagano A; Tsumura H; Iwamoto Y
    World J Surg Oncol; 2016 Dec; 14(1):306. PubMed ID: 27931230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
    Willemoe GL; Hertel PB; Bartels A; Jensen MB; Balslev E; Rasmussen BB; Mouridsen H; Ejlertsen B; Brünner N
    Eur J Cancer; 2009 Sep; 45(14):2528-36. PubMed ID: 19535243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
    McCarthy N; Boyle F; Zdenkowski N; Bull J; Leong E; Simpson A; Kannourakis G; Francis PA; Chirgwin J; Abdi E; Gebski V; Veillard AS; Zannino D; Wilcken N; Reaby L; Lindsay DF; Badger HD; Forbes JF;
    Breast; 2014 Apr; 23(2):142-51. PubMed ID: 24393617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial.
    Asleh K; Lyck Carstensen S; Tykjaer Jørgensen CL; Burugu S; Gao D; Won JR; Jensen MB; Balslev E; Laenkholm AV; Nielsen DL; Ejlertsen B; Nielsen TO
    Int J Cancer; 2019 May; 144(10):2578-2586. PubMed ID: 30411790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
    Kontopodis E; Kentepozidis N; Christophyllakis Ch; Boukovinas I; Kalykaki A; Kalbakis K; Vamvakas L; Agelaki S; Kotsakis A; Vardakis N; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):153-60. PubMed ID: 25398698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine in the management of metastatic breast cancer: a systematic review.
    Dent S; Messersmith H; Trudeau M
    Breast Cancer Res Treat; 2008 Apr; 108(3):319-31. PubMed ID: 17530427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG).
    Tomova A; Bartsch R; Brodowicz T; Tzekova V; Timcheva C; Wiltschke C; Gerges DA; Pawlega J; Spanik S; Inbar M; Zielinski CC
    Breast Cancer Res Treat; 2010 Jan; 119(1):169-76. PubMed ID: 19768533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
    JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
    Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E
    Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
    Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
    Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
    Chan S; Romieu G; Huober J; Delozier T; Tubiana-Hulin M; Schneeweiss A; Lluch A; Llombart A; du Bois A; Kreienberg R; Mayordomo JI; Antón A; Harrison M; Jones A; Carrasco E; Vaury AT; Frimodt-Moller B; Fumoleau P
    J Clin Oncol; 2009 Apr; 27(11):1753-60. PubMed ID: 19273714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
    Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
    Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
    Del Mastro L; Fabi A; Mansutti M; De Laurentiis M; Durando A; Merlo DF; Bruzzi P; La Torre I; Ceccarelli M; Kazeem G; Marchi P; Boy D; Venturini M; De Placido S; Cognetti F
    BMC Cancer; 2013 Mar; 13():164. PubMed ID: 23537313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
    Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
    Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.